Literature DB >> 31329211

Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis.

Marie Ryan1, Mark Heverin1, Russell L McLaughlin2, Orla Hardiman1.   

Abstract

IMPORTANCE: Heritability describes the proportion of variance in the risk of developing a condition that is explained by genetic factors. Although amyotrophic lateral sclerosis (ALS) is known to have a complex genetic origin, disease heritability remains unclear.
OBJECTIVES: To determine the extent of ALS heritability and assess the association of sex with disease transmission. DESIGN, SETTING, AND PARTICIPANTS: A prospective population-based parent-offspring heritability study was conducted from January 1, 2008, to December 31, 2017 to assess ALS heritability, and was the first study to assess heritability in the context of known gene mutations of large effect. A total of 1123 incident cases of ALS, diagnosed according to the El Escorial criteria and recorded on the Irish ALS register, were identified. Ninety-two individuals were excluded (non-Irish parental origin [n = 86] and familial ALS [n = 6]), and 1117 patients were included in the final analysis. MAIN OUTCOMES AND MEASURES: Annual age-specific and sex-specific standardized ALS incidence and mortality-adjusted lifetime risk were determined. Sex-specific heritability estimates were calculated for the overall study cohort, for those known to carry the C9orf72 (OMIM 614260) variant, and for those with no known genetic risk.
RESULTS: A total of 32 parent-child ALS dyads were identified during the study period. Affected offspring were younger at the onset of disease (mean age, 52.0 years; 95% CI, 48.8-55.3 years) compared with their parents (mean age, 69.6 years; 95% CI, 62.4-76.9 years; P = .008). Lifetime risk of developing ALS in first-degree relatives of individuals with ALS was increased compared with the general population (1.4% [32 of 2234] vs 0.3% [2.6 of 1000]; P < .001). Mean lifetime heritability of ALS for the overall study cohort was 52.3% (95% CI, 42.9%-61.7%) and 36.9% (95% CI, 19.8%-53.9%) for those with no known genetic risk. Heritability estimates were highest in mother-daughter pairings (66.2%; 95% CI, 58.5%-73.9%). CONCLUSIONS AND RELEVANCE: This population-based study confirms that up to 50% of variance in ALS has a genetic basis, and that the presence of the C9orf72 variant is an important determinant of heritability. First-degree relatives of individuals with ALS without a known genetic basis remain at increased risk of developing ALS compared with the general population. A higher heritability estimate in mother-daughter pairings points to a sex-mediated effect that has been previously unrecognized.

Entities:  

Year:  2019        PMID: 31329211      PMCID: PMC6646974          DOI: 10.1001/jamaneurol.2019.2044

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  16 in total

1.  Motoneuron Diseases.

Authors:  Francesco Lotti; Serge Przedborski
Journal:  Adv Neurobiol       Date:  2022

2.  Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Jennifer A Fifita; Sandrine Chan Moi Fat; Emily P McCann; Kelly L Williams; Natalie A Twine; Denis C Bauer; Dominic B Rowe; Roger Pamphlett; Matthew C Kiernan; Vanessa X Tan; Ian P Blair; Gilles J Guillemin
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

Review 3.  Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

Review 4.  Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

5.  Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis.

Authors:  Sai Zhang; Johnathan Cooper-Knock; Annika K Weimer; Minyi Shi; Tobias Moll; Jack N G Marshall; Calum Harvey; Helia Ghahremani Nezhad; John Franklin; Cleide Dos Santos Souza; Ke Ning; Cheng Wang; Jingjing Li; Allison A Dilliott; Sali Farhan; Eran Elhaik; Iris Pasniceanu; Matthew R Livesey; Chen Eitan; Eran Hornstein; Kevin P Kenna; Jan H Veldink; Laura Ferraiuolo; Pamela J Shaw; Michael P Snyder
Journal:  Neuron       Date:  2022-01-18       Impact factor: 18.688

6.  High-Throughput Genetic Testing in ALS: The Challenging Path of Variant Classification Considering the ACMG Guidelines.

Authors:  Serena Lattante; Giuseppe Marangi; Paolo Niccolò Doronzio; Amelia Conte; Giulia Bisogni; Marcella Zollino; Mario Sabatelli
Journal:  Genes (Basel)       Date:  2020-09-24       Impact factor: 4.096

7.  Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study.

Authors:  Monika Barczewska; Stanisław Maksymowicz; Izabela Zdolińska-Malinowska; Tomasz Siwek; Mariusz Grudniak
Journal:  Stem Cell Rev Rep       Date:  2020-10       Impact factor: 5.739

8.  Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases.

Authors:  Lyndal Henden; Natalie A Twine; Piotr Szul; Emily P McCann; Garth A Nicholson; Dominic B Rowe; Matthew C Kiernan; Denis C Bauer; Ian P Blair; Kelly L Williams
Journal:  NPJ Genom Med       Date:  2020-08-07       Impact factor: 8.617

Review 9.  Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.

Authors:  Xiaoqiang Tang; Arturo Toro; Sahana T G; Junli Gao; Jessica Chalk; Björn Oskarsson; Ke Zhang
Journal:  Mol Neurodegener       Date:  2020-06-08       Impact factor: 14.195

10.  ALS in Danish Registries: Heritability and links to psychiatric and cardiovascular disorders.

Authors:  Betina B Trabjerg; Fleur C Garton; Wouter van Rheenen; Fang Fang; Robert D Henderson; Preben Bo Mortensen; Esben Agerbo; Naomi R Wray
Journal:  Neurol Genet       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.